Tango Therapeutics (TNGX) Cash from Financing Activities (2020 - 2026)

Tango Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $79.8 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 3992200.0% year-over-year to $79.8 million; the TTM figure through Mar 2026 stood at $302.3 million (up 6354.82% YoY), while the FY2025 annual figure was $222.5 million, up 366.81% from the prior year.
• Cash from Financing Activities was $79.8 million for Q1 2026 at Tango Therapeutics, down from $219.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $219.4 million in Q4 2025 to a low of $2000.0 in Q1 2025.
• Historically, Cash from Financing Activities has averaged $25.5 million across 5 years, with a median of $969000.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities tumbled 100.0% in 2025, then surged 3992200.0% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $527000.0 in 2022, then jumped by 178.37% to $1.5 million in 2023, then tumbled by 33.95% to $969000.0 in 2024, then soared by 22539.42% to $219.4 million in 2025, then tumbled by 63.6% to $79.8 million in 2026.
• The last three Cash from Financing Activities figures came in at $79.8 million (Q1 2026), $219.4 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.